• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23210 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2027     Belgian Health Care Knowledge Centre (KCE) Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2025     Norwegian Medical Products Agency (NOMA) Intravenous ketamine for treatment-resistant depression
2025     Belgian Health Care Knowledge Centre (KCE) Economic evaluation of whole genome sequencing for children with developmental disorders (Study 2024-09)
2025     Belgian Health Care Knowledge Centre (KCE) Update of prostate cancer screening recommendations (Study 2024-10)
2025     Belgian Health Care Knowledge Centre (KCE) Update of breast cancer screening recommendations (Study 2024-11)
2025     Belgian Health Care Knowledge Centre (KCE) Evaluation of novel blood-based brain biomarkers for mild traumatic brain injuries (Study 2023-11)
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection of graft damage in kidney and heart recipient patients using donor-derived free DNA (dd-cfDNA)]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Branched endovascular prostheses for the treatment of aortic arch pathology]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and clinical effectiveness of cryoanalgesia in pediatric patients after surgical intervention for pectus excavatum]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of care models based on the incorporation of psychologists in primary care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of ex vivo confocal microscopy during Mohs surgery for basal cell carcinomas]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline (CPG) update palliative care]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical practice guideline on deprescribing antidepressants]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [SSRI/SSNRI: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cimicifuga: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for major liver resection]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Alternative methods to coercive measures]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostic precision with liquid biopsy for asymptomatic ovarian cancer]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Quality indicators for the care and services provided in long-term left ventricular assist device implantation programs]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Paclitaxel-coated balloon dilatation in recurrent bulbar urethral strictures]
2024     Andalusian Health Technology Assessment Area (AETSA) [Liquid biopsy in lung neoplasms: diagnosis, prognosis and treatment adequacy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism by MS/MS. Update: Carnitine uptake deficiency; very long chain acyl-CoA dehydrogenase deficiency]
2024     NIHR Health Technology Assessment programme Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluation
2024     National Institute for Health and Care Excellence (NICE) CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. NICE diagnostics guidance 59
2024     National Institute for Health and Care Excellence (NICE) Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus. NICE interventional procedures guidance 789
2024     National Institute for Health and Care Excellence (NICE) Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury. NICE interventional procedures guidance 792
2024     National Institute for Health and Care Excellence (NICE) Caval valve implantation for tricuspid regurgitation. NICE interventional procedures guidance 791
2024     National Institute for Health and Care Excellence (NICE) Phrenic nerve pacing for congenital central hypoventilation syndrome. NICE interventional procedures guidance 790
2024     National Institute for Health and Care Excellence (NICE) Single-step scaffold insertion for repairing symptomatic chondral knee defects. NICE interventional procedures guidance 793
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal). NICE technology appraisal guidance 966
2024     National Institute for Health and Care Excellence (NICE) Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 968
2024     National Institute for Health and Care Excellence (NICE) Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal). NICE technology appraisal guidance 969
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over. NICE technology appraisal guidance 967
2024     National Institute for Health and Care Excellence (NICE) Remdesivir and tixagevimab plus cilgavimab for treating COVID-19. NICE technology appraisal guidance 971
2024     National Institute for Health and Care Excellence (NICE) Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments. NICE technology appraisal guidance 970
2024     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. NICE technology appraisal guidance 975
2024     National Institute for Health and Care Excellence (NICE) Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 974
2024     National Institute for Health and Care Excellence (NICE) Atogepant for preventing migraine. NICE technology appraisal guidance 973
2024     National Institute for Health and Care Excellence (NICE) Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal). NICE technology appraisal guidance 972
2024     National Institute for Health and Care Excellence (NICE) Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 978
2024     National Institute for Health and Care Excellence (NICE) Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over. NICE technology appraisal guidance 977
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 976
2024     National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 980
2024     National Institute for Health and Care Excellence (NICE) Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation. NICE technology appraisal guidance 979
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 983
2024     National Institute for Health and Care Excellence (NICE) Voxelotor for treating haemolytic anaemia caused by sickle cell disease. NICE technology appraisal guidance 981
2024     National Institute for Health and Care Excellence (NICE) Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal). NICE technology appraisal guidance 982
2024     National Institute for Health and Care Excellence (NICE) Tafamidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 984
2024     National Institute for Health and Care Excellence (NICE) Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma. NICE technology appraisal guidance 985
2024     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal). NICE technology appraisal guidance 987
2024     National Institute for Health and Care Excellence (NICE) Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over. NICE technology appraisal guidance 986
2024     National Institute for Health and Care Excellence (NICE) Tenecteplase for treating acute ischaemic stroke. NICE technology appraisal guidance 990
2024     National Institute for Health and Care Excellence (NICE) Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B. NICE technology appraisal guidance 989
2024     National Institute for Health and Care Excellence (NICE) Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis. NICE technology appraisal guidance 988
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy. NICE technology appraisal guidance 992
2024     National Institute for Health and Care Excellence (NICE) Burosumab for treating X-linked hypophosphataemia in adults. NICE technology appraisal guidance 99
2024     National Institute for Health and Care Excellence (NICE) Abaloparatide for treating osteoporosis after menopause. NICE technology appraisal guidance 991
2024     National Institute for Health and Care Excellence (NICE) Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal). NICE technology appraisal guidance 994
2024     National Institute for Health and Care Excellence (NICE) Linzagolix for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 996
2024     National Institute for Health and Care Excellence (NICE) Relugolix for treating hormone-sensitive prostate cancer. NICE technology appraisal guidance 995
2024     National Institute for Health and Care Excellence (NICE) Risankizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 998
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 997
2024     National Institute for Health and Care Excellence (NICE) Vibegron for treating symptoms of overactive bladder syndrome. NICE technology appraisal guidance 999
2024     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment. NICE technology appraisal guidance 1001
2024     National Institute for Health and Care Excellence (NICE) Iptacopan for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1000
2024     National Institute for Health and Care Excellence (NICE) Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. NICE technology appraisal guidance 1005
2024     National Institute for Health and Care Excellence (NICE) Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion. NICE technology appraisal guidance 1004
2024     National Institute for Health and Care Excellence (NICE) Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over. NICE technology appraisal guidance 1003
2024     National Institute for Health and Care Excellence (NICE) Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over. NICE technology appraisal guidance 1002
2024     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal). NICE technology appraisal guidance 1006
2024     National Institute for Health and Care Excellence (NICE) Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. NICE technology appraisal guidance 1007
2024     National Institute for Health and Care Excellence (NICE) Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments. NICE technology appraisal guidance 1008
2024     National Institute for Health and Care Excellence (NICE) Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. NICE technology appraisal guidance 1009
2024     NIHR Health Technology Assessment programme Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT
2024     NIHR Health Technology Assessment programme Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Magnetic resonance neurography in peripheral neuropathy or plexopathy]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: overview – comparison, based on health profile, of the use of primary care medical services by persons registered with a family physician and those who are not]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: COVID-19 - optimal use of parmacological treatments]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Public health preparedness for mass gatherings
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: hormone therapy for the management of the clinical manifestations of menopause]
2024     NIHR Health Technology Assessment programme Specific phobias in children with moderate to severe intellectual disabilities: SPIRIT, an adaptation and feasibility study
2024     NIHR Health Technology Assessment programme Antidepressants for pain management in adults with chronic pain: a network meta-analysis
2024     NIHR Health Technology Assessment programme MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis
2024     Penn Medicine Center for Evidence-based Practice (CEP) Impact of workforce racial and ethnic diversity on patient health and healthcare outcomes
2024     NIHR Health Services and Delivery Research programme Consequences of how third sector organisations are commissioned in the NHS and local authorities in England: a mixed-methods study
2024     NIHR Health Technology Assessment programme Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling
2024     NIHR Health Technology Assessment programme Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
2024     NIHR Health Technology Assessment programme The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024     NIHR Health Technology Assessment programme Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024     Penn Medicine Center for Evidence-based Practice (CEP) Hyperbaric oxygen therapy for injury recovery among athletes